MedLever

236 posts

MedLever banner
MedLever

MedLever

@MedLever

The automation platform for radiation oncology.

Mountain View, CA 가입일 Ağustos 2012
288 팔로잉138 팔로워
MedLever 리트윗함
MedLever 리트윗함
Neha Vapiwala
Neha Vapiwala@NehaVapiwala·
Cancer’s impact transcends borders. Mission-driven @ASTRO_org members like @TamerRefaatMD are leading ASTRO’s charge to address #radiotherapy care access & quality on a global scale. His words are inspiring, but it’s his actions - alongside those of many other committed colleagues - that will move the needle. Come listen & learn how to get more involved!
ASTRO@ASTRO_org

NEW President's Corner Member Spotlight - Tamer Refaat, MD, PhD, MSCI In the latest ASTRO President's Member Spotlight, ASTRO President Neha Vapiwala, MD, FASTRO, speaks with Tamer Refaat, MD, PhD, MSCI, vice-chair of the ASTRO International Committee, about the new ASTRO International Ambassadors program. @NehaVapiwala @TamerRefaatMD Watch the video: ow.ly/ruFQ50XT6jZ

English
0
4
10
637
MedLever 리트윗함
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
**ANNOUNCEMENT** Our growth continues with strategic expansions and our recruiting for FOUR (yes 4) new physicians to join our remarkable team! Includes the Vice Chair of Research, Director of Brachytherapy, and two additional clinical-academic faculty positions Read more... @NicholasZaorsky @angela_jia_ @lauren_henke @Soum_Roy_RadOnc @HaleyPerlow @APrice_BeamOn @NRGonc @ACRORadOnc @ARRO_org @ASCO @IJROBP @RadOncUH @a_dalpra @AmarUKishan @HimanshuNagarMD @PCFnews @urotoday
Daniel E Spratt tweet media
English
2
19
84
14.3K
MedLever 리트윗함
ASTRO
ASTRO@ASTRO_org·
ASTRO is deeply disturbed by the inaccurate, inappropriate, and irresponsible NBC News piece on IORT. We feel this story harms care for breast cancer patients & have strongly rebutted it through our Breast Cancer Resource Panel & a letter from ASTRO CEO, Vivek S Kavadi, MD to NBC News. Read each here: Breast Resource Panel Statement ow.ly/aicz50X9ty1 Letter to NBC News from Dr. Vivek S. Kavadi ow.ly/Hvy550X9txZ
English
2
52
132
22.9K
MedLever 리트윗함
ASTRO
ASTRO@ASTRO_org·
Missing #ASTRO25 already? Watch ASTRO's 2025 Annual Meeting onDemand. Access more than 200 hours of scientific and educational content from leading experts & claim 190+ AMA PRA Category 1™ CME credits. All available on the 2025 Annual Meeting Portal. Learn more and purchase now: ow.ly/mRJ650X5L5p
ASTRO tweet media
English
0
4
7
2.2K
MedLever 리트윗함
David Sher
David Sher@DavidSherMD·
Terrific thread by @seanmmcbride While it is important to keep an open mind when faced with bizarre results, the raw survival numbers are almost incomprehensible. In the ITT population: - In the IMRT arm, there were 29 recurrences (Table 1) and 23 deaths due to cancer (Table S1). - In the IMPT arm, there were 25 recurrences and 11 deaths due to cancer. - Thus, 79% of IMRT recurrences led to cancer-specific mortality, versus only 44% of IMPT recurrences. In the PP population: - In the IMRT arm, there were 23 recurrences and 27 deaths (Fig 3b), of which 10 were without progression (Table 1). We don’t know further causes of death. - In the IMPT arm, there were 23 recurrences and only 16 deaths, of which 9 were without progression. - Thus, 74% (17/23) IMRT recurrent patients died, and only 30% (7/23) IMPT recurrent patients died. These survival after salvage numbers aren’t just statistically significant, they are miraculous. To have 70% of R/M HNSCC alive after IMPT has to reflect something beyond biology. I’m looking forward to the final publication and analysis, but there is a “know it when you see it" phenomenon with confounding, and that appears to hold here.
Sean McBride@seanmmcbride

1/n Agree. David and team ran an outstanding trial. And I think there's less discordance btw TORPEDO and the MDA RCT than the discourse suggests. Both trials are essentially demonstrating some QOL/tox benefits for protons in the end-of-treatment/immediate post tx periods. Rate of 12 mon G tube dependence are minimal in both arms in both trials. And the PFS/OS end-points at 3 years are consistent (no benefit to proton). brief🧵#ASTRO25 #hncsm

English
2
8
16
3.3K
MedLever
MedLever@MedLever·
🚀 Instant Documentation, Zero Hassle In just 2-5 minutes, you can complete clinical radiotherapy documentation and launch all care paths from a single interaction. ✅ Fast: Generate high-quality, customized documents instantly ✅ Smart: Automation ensures accuracy and consistency ✅ Seamless: Signed documents sync directly with your EMR ⚡ Work smarter, streamline documentation, and stay focused on patient care. 📍 lnkd.in/gxtf2vWw
MedLever tweet media
English
0
0
2
94
MedLever
MedLever@MedLever·
🤝 True Partnership, Real Impact with MedLever At MedLever, we understand the importance of true partnership. When we collaborate with clinics, it's about creating workflows that work best for them. From the initial implementation to ongoing revisions, we're committed to optimizing the platform to fit each clinic's unique needs. Our focus is on: ✨ Customization – Tailoring workflows to your specific processes ✨ Personalization – Adapting the platform to meet your goals ✨ Collaboration – Partnering with your team for continuous improvement With MedLever, clinics gain a lifetime commitment to support and assistance—because patient outcomes come first.
MedLever tweet media
English
0
0
0
144
MedLever
MedLever@MedLever·
As we look back and reflect on a year of growth, innovation, and collaboration. 2024's achievements have brought us closer to our mission of advancing patient care and operational excellence. Thank you to our clients and partners for making this success possible—here’s to an even brighter 2025! 🌱
MedLever tweet media
English
0
1
1
92
MedLever
MedLever@MedLever·
Thank you to @DrSpratticus, @RaedZuhour, @angela_jia_ , and the team at University Hospitals for their leadership in advancing radiation oncology workflows. The comprehensive modeling of their processes was achieved with an impressive balance of standardization, customization, and flexibility, accommodating the unique needs of the patient, their physicians, and the clinical teams.
English
0
0
1
53
MedLever 리트윗함
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
9/ Revolutionizing workflows with our end to end custom built learning health system for radonc with @MedLever. Led by @RaedZuhour , our team built a learning radiation oncology EMR—fully automating orders, documentation, nursing tasks, billing, and physics workflows. Gets better and better every iteration.
English
2
2
13
1.9K
MedLever
MedLever@MedLever·
@ParikhSimul @oncoramed @JordanJ65544091 We use Aria or MOSAIQ as the source of truth, so everything we generate ends up there. We can work with your technical team to determine how that content gets into Epic at the encounter level.
English
0
0
0
66
MedLever
MedLever@MedLever·
@ParikhSimul @oncoramed @JordanJ65544091 We can auto generate all the needed documents, provide a medium for multi-department access and set up the tasks and notifications to clinical and revenue cycle team members.
English
1
0
0
150
MedLever 리트윗함
ASTRO
ASTRO@ASTRO_org·
We are one week away from the #ASTRO23 Annual Meeting & there is still time to register! Register today: ow.ly/Ov2Y50POm10
ASTRO tweet media
English
0
9
16
3.1K
MedLever
MedLever@MedLever·
Are you attending #ASTRO23? Come check us out at Booth 3523. @medlever is the air-traffic control for your clinic and the digital assistant for your #radonc workflow. See our automation engine simplify documentation and our electronic task-tracking whiteboards keep the whole department in sync. See you in San Diego!
English
10
35
296
36.3K
MedLever 리트윗함
RadOncUH
RadOncUH@RadOncUH·
**HIRING @ UH Seidman Cancer Center's @RadOncUH** Calling Medical Physicists- We are recruiting! Excited to announce we have grown by >40% in past 2 yrs, and have 4 new LINACs soon to go live and innovative new software @MedLever @RaySearch @KashaniRojano @DrSpratticus
English
1
11
23
8.7K
MedLever
MedLever@MedLever·
A new year brings new breakthroughs in #oncology. In 2023, the oncology space will focus on: 🟣 Genetic Testing 🟣 Targeted Immunotherapies 🟣 Finding and Treating Cancer at the Same Time 🟣 And More! What are you most excited to see in the oncology space in the new year?
MedLever tweet media
English
0
0
0
112